Technology Update SessionSession 2A In this session, we will review the findings of a multi-center clinical trial that evaluated outcomes with Advanced Bionics' system for remote programming of a cochlear implant system. An investigational version of the Target CI programming software was used in the clinical trial to remotely program Marvel CI cochlear implant sound processors. Additional studies will be reviewed, documenting outcomes of patients with the commercially approved version of this software system. The technical infrastructure that enables remote programming will also be discussed.Clinical trial results showed that speech recognition was similar for both programming conditions, which supported the primary efficacy endpoint. Questionnaires collected during that study showed that both investigators and participants had a positive remote programming experience. The post-market studies further support outcomes equivalence between in-office and remote programming, while subjects and audiologists report increased convenience and reduced costs associate when unnecessary in-person clinic visits can be avoided. Jason Galster, PhD, is Sonova's Vice President of Clinical Strategy. He works with a global network of teams on the clinical development, regulatory clinical affairs, and post-market scientific investigation of hearing instruments. His personal research interests include audio signal processing for the treatment of hearing loss and the measurement of hearing outcomes during daily life.
|